Evidence for Rebound?
- Experience limited to 22 PAH patients
- 5 pts had treatment discontinued after dose reduction
- 7 pts had treatment interrupted for 2-14 days
- 10 pts had open-label treatment discontinued
- PAH-related adverse experiences
- 1 pt with aggravated PAH (29 days after d/c)
- No evidence in hypertensive or CHF patients